- Home
- TNGX vs MIN Comparison
TNGX vs MIN Comparison
Compare TNGX & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- MIN
- Stock Information
- Founded
- TNGX 2014
- MIN 1988
- Country
- TNGX United States
- MIN United States
- Employees
- TNGX N/A
- MIN N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- MIN Trusts Except Educational Religious and Charitable
- Sector
- TNGX Health Care
- MIN Finance
- Exchange
- TNGX Nasdaq
- MIN Nasdaq
- Market Cap
- TNGX 351.2M
- MIN 303.8M
- IPO Year
- TNGX N/A
- MIN N/A
- Fundamental
- Price
- TNGX $6.73
- MIN $2.65
- Analyst Decision
- TNGX Strong Buy
- MIN
- Analyst Count
- TNGX 6
- MIN 0
- Target Price
- TNGX $12.20
- MIN N/A
- AVG Volume (30 Days)
- TNGX 2.5M
- MIN 331.0K
- Earning Date
- TNGX 08-06-2025
- MIN 01-01-0001
- Dividend Yield
- TNGX N/A
- MIN 7.31%
- EPS Growth
- TNGX N/A
- MIN N/A
- EPS
- TNGX N/A
- MIN 0.08
- Revenue
- TNGX $40,990,000.00
- MIN N/A
- Revenue This Year
- TNGX N/A
- MIN N/A
- Revenue Next Year
- TNGX N/A
- MIN N/A
- P/E Ratio
- TNGX N/A
- MIN $33.38
- Revenue Growth
- TNGX 10.09
- MIN N/A
- 52 Week Low
- TNGX $1.03
- MIN $2.52
- 52 Week High
- TNGX $12.02
- MIN $2.88
- Technical
- Relative Strength Index (RSI)
- TNGX 75.80
- MIN 41.15
- Support Level
- TNGX $5.75
- MIN $2.65
- Resistance Level
- TNGX $6.40
- MIN $2.70
- Average True Range (ATR)
- TNGX 0.47
- MIN 0.03
- MACD
- TNGX 0.02
- MIN -0.01
- Stochastic Oscillator
- TNGX 89.51
- MIN 0.00
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.